Keywords: Type 2 diabetes, Physician prescribing, Reimburse,entm Decison Resources, Januvai, Galvus, Onglyza, Victoza, Bydureon, Tradjenta, Nesina
Most surveyed physicians in Europe expect to increase Rxing of GLP-1 analogues and DPP-IV inhibitors
Article | 18 August 2011
Almost all surveyed physicians in each of the top European Union countries (France, Germany, Italy, Spain and the UK) currently ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
